Unknown PHASE1 INTERVENTIONAL 1-arm NCT03576014

Evaluate Tolerability and Safety of BD03 for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient

A Prospective, Open, Dose-escalation, Multi-center, Phase 1 Trial to Evaluate Tolerability and Safety of Intramuscularly Administered BD03, a DNA Vaccine for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient

Sponsor: SL BIGEN

Conditions BK Virus Infection Cytomegalovirus Infections Preventation of BK Virus Reactivation Preventation of Cytomegalovirus Reactivation

Interventions BD03

Updated 6 times since 2018 Last updated: Jun 21, 2018 Started: Apr 27, 2018 Primary completion: Jan 30, 2019 Completion: Jul 24, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03576014, this PHASE1 trial focuses on BK Virus Infection and Cytomegalovirus Infections and remains ongoing. Sponsored by SL BIGEN, it has been updated 6 times since 2018, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE1
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jun 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Aug 2018 — Jun 2020 [monthly]

Recruiting PHASE1

First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SL BIGEN
SL VAXiGEN

Data source: SL VAXiGEN

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea